DOCSLIB.ORG

The Endocannabinoid System in Local and Systemic Inflammation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Endocannabinoid System in Local and Systemic Inflammation Colloquium Series on Integrated Systems Physiology KELLY • ET AL • ET KELLY Colloquium Lectures on Series ISSN: 2154-560X The Endocannabinoid System in Integrated Systems Physiology From Molecule to Function to Disease Local and Systemic Inflammation THE ENDOCANNABINOID SYSTEM IN LOCAL AND SYSTEMIC INFLAMMATION THE ENDOCANNABINOID SYSTEM IN LOCAL Series Editors: D. Neil Granger, LSU Health Sciences, Shreveport Joey Granger, University of Mississippi Medical Center Regulation of Gastrointestinal Mucosal Growth, Second Edition Rao N. Jadalanki, University of Maryland School of Medicine, Baltimore Veterans Affairs Medical Center Jian-Ying Wang, University of Maryland School of Medicine, Baltimore Veterans Affairs Medical Center The mammalian gastrointestinal mucosa is a rapidly self-renewing tissue in the body, and its homeostasis is preserved through the strict regulation of epithelial cell proliferation, growth arrest, and apoptosis. The control of the growth of gastrointestinal mucosa is unique and, compared with most other tissue in the body, complex. Mucosal growth is regulated by the same hormones that alter metabolism in other tissues, but the gastrointestinal mucosa also responds to host events triggered by the ingestion and presence of food within the digestive tract. These gut hormones and peptides regulate the growth of the exocrine pancreas, gallbladder epithelium, and the mucosa of the oxyntic gland region of the stomach and the small and large intestines. Luminal factors, including nutrients or other dietary factors, secretions, and microbes that occur within the lumen and distribute over a proximal-to-distal gradient, are also crucial for maintenance of normal gut mucosal regeneration and could explain the villous-height-crypt-depth gradient and variety of adaptation, since these factors are diluted, absorbed, and destroyed as they pass down the digestive tract. Recently, intestinal stem cells, cellular polyamines, and noncoding RNAs are shown to play an important role in the regulation of gastrointestinal mucosal growth under physiological and various pathological conditions. In this book, we highlight key issues and factors that control gastrointestinal mucosal growth and homeostasis, with special emphasis on the mechanisms through which epithelial renewal and apoptosis are regulated at the cellular and molecular levels. About Morgan & Claypool Publishers This volume is a printed version of a work that appears in the Colloquium Digital Library of Life Sciences. Colloquium books provide concise, original presentations of important research topics, authored by invited experts. All books are available in digital & print formats. For more information, visit store.morganclaypool.com morgan & store.morganclaypool.com claypool MELANIE E.M. KELLY • CHRISTIAN LEHMANN • JUAN ZHOU The Endocannabinoid System in Local and Systemic Inflammation ii Colloquium Digital Library of Life Sciences TheColloquium Digital Library of Life Sciences is an innovative information resource for researchers, instructors, and students in the biomedical life science community, including clinicians. Each PDF e-book available in the Colloquium Digital Library is an accessible overview of a fast-moving basic science research topic, authored by a prominent expert in the field. They are intended as time-sav- ing pedagogical resources for scientists exploring new areas outside of their specialty. They are also excellent tools for keeping current with advances in related fields, as well as refreshing one’s under- standing of core topics in biomedical science. For the full list of available books, please visit: colloquium.morganclaypool.com Each book is available on our website as a PDF download. Access is free for readers at institutions that license the Colloquium Digital Library. Please e-mail [email protected] for more information. iii Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease Editors D. Neil Granger Louisiana State University Health Sciences Center Joey P. Granger University of Mississippi Medical Center Physiology is a scientific discipline devoted to understanding the functions of the body. It addresses function at multiple levels, including molecular, cellular, organ, and system. An appreciation of the processes that occur at each level is necessary to understand function in health and the dysfunction associated with disease. Homeostasis and integration are fundamental principles of physiology that account for the relative constancy of organ processes and bodily function even in the face of substantial environmental changes. This constancy results from integrative, cooperative interactions of chemical and electrical signaling processes within and between cells, organs and systems. This eBook series on the broad field of physiology covers the major organ systems from an integrative perspective that addresses the molecular and cellular processes that contribute to homeostasis. Material on pathophysiology is also included throughout the eBooks. The state-of the-art treatises were produced by leading experts in the field of physiology. Each eBook includes stand-alone information and is intended to be of value to students, scientists, and clinicians in the biomedical sciences. Since physiological concepts are an ever-changing work-in-progress, each contributor will have the opportunity to make periodic updates of the covered material. Published titles (for future titles please see the website, www.morganclaypool.com/toc/isp/1/1) iv Copyright © 2017 by Morgan & Claypool All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means—electronic, mechanical, photocopy, recording, or any other except for brief quotations in printed reviews, without the prior permission of the publisher. The Endocannabinoid System in Local and Systemic Inflammation Melanie E. M. Kelly, Christian Lehmann, and Juan Zhou www.morganclaypool.com ISBN: 9781615047482 paperback ISBN: 9781615047499 ebook DOI: 10.4199/C00151ED1V01Y201702ISP074 A Publication in the Morgan & Claypool series COLLOQUIUM SERIES ON INTEGRATED SYSTEMS PHYSIOLOGY: FROM MOLECULE TO FUNCTION TO DISEASE Lecture #74 Series Editors: D. Neil Granger, LSU Health Sciences Center, and Joey P. Granger, University of Mississippi Medical Center ISSN 2154-560X print ISSN 2154-5626 electronic The Endocannabinoid System in Local and Systemic Inflammation Melanie E. M. Kelly Dalhousie University Christian Lehmann Dalhousie University Juan Zhou Dalhousie University COLLOQUIUM SERIES ON INTEGRATED SYSTEMS PHYSIOLOGY: FROM MOLECULE TO FUNCTION TO DISEASE #74 &MC MORGAN & CLAYPOOL LIFE SCIENCES vi ABSTRACT This book focuses on the role of the endocannabinoid system in local and systemic inflammation, with individual chapters written by experts in the field of cannabinoid research and medicine. The topics explore the actions of the endocannabinoid system on the immune system, including neu- roinflammation in autoimmune disorders such as multiple sclerosis, and in neurodegenerative dis- orders such as Huntington’s and Alzheimer’s, as well as local and systemic inflammatory conditions affecting organs including the eye (uveitis and corneal inflammation), the bladder (interstitial cys- titis), pancreas (diabetes), cardiovascular system (stroke), joints (arthritis), and sepsis. The objective of this book is to provide knowledge transfer on the use of cannabinoids in inflammatory disease by critically examining preclinical and clinical research on the immunomodulatory actions of the endocannabinoid system, with specific emphasis on the actions of cannabinoids in diseases where inflammation is a prominent component. By drawing these results together, we seek to provide fur- ther understanding of the complexities of endocannabinoid system modulation of immune function and identify potential uses and limitations for cannabinoid-based therapeutics. KEY WORDS Alzheimer’s disease, amyloid β, arthritis, cannabinoids, cannabinoid receptors, cannabis, CNS injury, diabetic retinopathy, dronabinol, endocannabinoids, endocannabinoid system, endotox- in-induced uveitis, experimental autoimmune encephalomyelitis, experimental autoimmune uve- oretinitis, Huntington’s disease, immune system, immune cells, inflammation, marijuana, multiple sclerosis, Nabiximols, neuroinflammation, neurodegeneration, neuroprotection, ocular inflamma- tion, pain, phytocannabinoids, proliferative vitreoretinopathy, spasticity, Sativex® vii Contents Preface . xi 1 Inflammation and the Endocannabinoid System . 1 1.1 Introduction . 1 1.2 Cannabinoid Type 1 Receptor . 2 1.3 Cannabinoid Type 2 Receptor . 4 1.4 Other Receptors and Ligands . 6 1.5 Modulation of the Inflammatory Immune Response by the Endocannabinoid System . 7 1.6 Conclusions . 8 2 Cannabinoids in Multiple Sclerosis . 9 2.1 Multiple Sclerosis. 10 2.1.1 Etiology �������������������������������������������������������������������������������������������� 10 2.1.2 Pathology and Symptoms of Multiple Sclerosis . 11 2.1.3 Current Treatments for Multiple Sclerosis . 12 2.2 Cannabinoids in Multiple Sclerosis . 13 2.2.1 Experimental Autoimmune Encephalomyelitis Animal Models . 13 2.2.2 Clinical Data . 15 2.2.3 Tolerability of Cannabinoids . 17 2.3 Concluding Remarks and Future Directions . 18 3 Huntington’s Disease and the Endocannabinoid System . 19 3.1 Huntington’s Disease . 21 3.2 Neuroinflammation in Huntington’s Disease . 22 3.3 The Management of euroinflammationN in Huntington’s
Load more

Recommended publications
  • Targeting the Endocannabinoid System to Reduce Nociception
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2011 Targeting the endocannabinoid system to reduce nociception Lamont Booker Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2419 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Targeting the Endocannabinoid System to Reduce Nociception A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. By Lamont Booker Bachelor’s of Science, Fayetteville State University 2003 Master’s of Toxicology, North Carolina State University 2005 Director: Dr. Aron H. Lichtman, Professor, Pharmacology & Toxicology Virginia Commonwealth University Richmond, Virginia April 2011 Acknowledgements The author wishes to thank several people. I like to thank my advisor Dr. Aron Lichtman for taking a chance and allowing me to work under his guidance. He has been a great influence not only with project and research direction, but as an excellent example of what a mentor should be (always willing to listen, understanding the needs of each student/technician, and willing to provide a hand when available). Additionally, I like to thank all of my committee members (Drs. Galya Abdrakmanova, Francine Cabral, Sandra Welch, Mike Grotewiel) for your patience and willingness to participate as a member. Our term together has truly been memorable! I owe a special thanks to Sheryol Cox, and Dr.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Cannabinoids for the Control of Experimental Multiple Sclerosis Pryce, Gareth
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Queen Mary Research Online Cannabinoids for the control of experimental multiple sclerosis Pryce, Gareth The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author For additional information about this publication click this link. https://qmro.qmul.ac.uk/jspui/handle/123456789/673 Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [email protected] 1 Cannabinoids for the control of experimental multiple sclerosis GARETH PRYCE Neuroimmunology Unit, Neuroscience & Trauma Barts and the London School of Medicine and Dentistry Queen Mary University of London UK 2 This thesis is dedicated in memory of my Dad, Glyn Pryce (1927-2010), with love and thanks. 3 ACKNOWLEDGEMENTS I wouldlike to thank DavidBaker andGavin Giovannoni for their supervision and providingme with the opportunity to undertake this thesis. I wouldlike to thank J.Ludovic Croxford, Sam Jackson, Sarah Al-Izki from the lab past and present; Ana Cabranes (RIP) and the Javier Fernadez-Ruiz laboratory in Madrid, Spain; the Vincenzo Di Marzio Laboratory Naples, Italy; the Andy Irving Laboratory, Dundee; the laboratories of Elga De Vries andSandra Amor at the Free University Amsterdam, The Netherlands and the laboratories of Ruth Ross and Roger Pertwee in Aberdeen and Alison Hardcastle University College London for providing me with supportive data and particularly Cristina Visintin and David Selwoodof University College London andCanbex for providingdata from contract Research organizations.
    [Show full text]
  • Laws, Rules, and Regulations
    LAWS, RULES, AND REGULATIONS August 2020 Asa Hutchinson, Governor John Clay Kirtley, Pharm.D. Executive Director Arkansas Department of Health Arkansas State Board of Pharmacy 322 South Main Street, Suite 600 Little Rock, AR 72201 Phone: 501.682.0190 Fax: 501.682.0195 [email protected] www.pharmacyboard.arkansas.gov 10/8/2020 Arkansas State Board of Pharmacy Members Lenora Newsome, P.D. President, Smackover Rebecca Mitchell, Pharm.D. Vice President/Secretary, Greenbrier Deborah Mack, P.D. Member, Bentonville Lynn Crouse, Pharm.D. Member, Lake Village Brian Jolly, Pharm.D. Member, Beebe Carol Rader, RN Public Member, Fort Smith Amy Fore, MHSA, FACMPE, FACHE Public Member, Fort Smith 10/8/2020 Board of Pharmacy Law Book - Acts Table of Contents Pharmacy Practice Act A 17-92-101 Definitions……………………………………………………… 1-4 17-92-102 Exemptions…………………………………………………….. 4-5 17-92-103 Pharmacy laws unaffected……………………………………... 5 17-92-104 Privilege tax unaffected……………………………………….. 5 17-92-105 Prohibited acts – Penalties……………………………………... 6 17-92-106 Injunctions……………………………………………………… 6 17-92-107 Prosecutions – Disposition of fines……………………………. 6 17-92-108 Fees…………………………………………………………….. 6-10 17-92-109 Prescriptions for optometrists………………………………….. 10 17-92-110 Prescriptive authority of advance practice nurses……………… 10 17-92-111 Construction of Acts 1997, No. 1204………………………….. 10 17-92-112 Prescriptions for physician assistants…………………………. 10 17-92-201 Members – Qualifications……………………………………… 11 17-92-202 Members – Oath……………………………………………… 11 17-92-203 Members – Compensation…………………………………….. 11 17-92-204 Organization and proceedings…………………………………. 12 17-92-205 Rules and regulations – Enforcement………………………….. 12-13 17-92-206 Issuance of bulletins – Annual Reports………………………... 14 17-92-207 Maintenance of office………………………………………….
    [Show full text]
  • Endocannabinoid System in a Planarian Model
    ENDOCANNABINOID SYSTEM IN THE PLANARIAN MODEL Katie Lynn Mustonen Thesis Prepared for the Degree of MASTER OF SCIENCE UNIVERSITY OF NORTH TEXAS December 2010 APPROVED: Barney J. Venables, Major Professor Kent D. Chapman, Committee Member Aaron P. Roberts, Committee Member Art J. Goven, Chair of the Department of Biological Sciences James D. Meernik, Acting Dean of the Robert B. Toulouse School of Graduate Studies Mustonen, Katie Lynn. Endocannabinoid System in a Planarian Model. Master of Science (Biology), December 2010, 138 pp., 22 tables, 9 figures, references, 452 titles. In this study, the presence and possible function of endocannabinoid ligands in the planarian is investigated. The endocannabinoids ananadamide (AEA) and 2- arachidonoylglycerol (2-AG) and entourage NAE compounds palmitoylethanolamide (PEA), stearoylethanolamide (SEA) and oleoylethanolamide (OEA) were found in Dugesia dorotocephala. Changes in SEA, PEA, and AEA levels were observed over the initial twelve hours of active regeneration. Exogenously applied AEA, 2-AG and their catabolic inhibition effected biphasic changes in locomotor velocity, analogous to those observed in murines. The genome of a close relative, Schmidtea mediterranea, courtesy of the University of Utah S. med genome database, was explored for cannabinoid receptors, none were found. A putative fatty acid amide hydrolase (FAAH) homolog was found in Schmidtea mediterranea. Copyright 2010 by Katie Lynn Mustonen ii ACKNOWLEDGEMENTS I would like to express my gratitude to my major professor and super-hero Dr. Barney Venables for his patience, understanding and encouragement. I would also like to thank my student colleagues who helped with so many little things and to especially acknowledge Cheryl Waggoner. Our paths were so similar, in reaching this milestone her absence is palpable.
    [Show full text]
  • 2006 ICRS Symposium Program
    1166 th AAnnnnuuaall SSyymmppoossiiuumm OOnn TThhee CCaannnnaabbiinnooiiddss 2006 Program . Registration June 24, 2006 (1600-2000) Day 1 Sunday, June 25th 7.50 - 8.00 OPENING REMARKS Session 1. SAR Studies and New Synthetic Molecules ¾ Chairs: Drs. Brian Thomas and Raj Razdan Page # THE RELEVANCE OF THE STERIC FACTOR Yehoshua Maor, Ruth Gallily IN THE BIOLOGICAL ACTIVITY OF CBD 8.00 DERIVATIVES – 1 and Raphael Mechoulam A TOOL IN IDENTIFYING NOVEL MOLECULAR TARGET FOR CANNABINOIDS 1-PENTYL-2-ARYL-4-(1- John W. Huffman, Lea W. Padgett, NAPHTHOYL)PYRROLES: A NEW 2 Matthew L. Isherwood, Jenny L. Wiley 8.15 CLASS OF HIGH AFFINITY LIGANDS and Billy R. Martin FOR THE CB1 AND CB2 RECEPTORS T.M. Fong, L.S. Lin, X-M Guan, D.J. Marsh, C-P Shen, J. Lao, D.S. Stribling, K.M. Rosko, H. Yu, Y. Feng, J.C. Xiao , L.H.T. Van der Ploeg, M.T. Goulet, W.K. DISCOVERY OF A NOVEL CB1R 3 8.30 Hagmann, T.J. Lanza, Jr., J.P. Jewell, P. Liu, S.K. Shah, H. Qi, X. Tong, J. Wang, and S. Xu, R. Gibson, B. INVERSE AGONIST Francis, S. Patel, A.M. Strack, D.E. MacIntyre and L.P. Shearman Yanan Zhang, Marcus Brackeen, Anne CONFORMATIONALLY-CONSTRAINED 4 Gilliam, Herbert Seltzman 8.45 ANALOGS OF SR141716 and Brian Thomas Session 2. Receptor Structure and Signal Transduction ¾ Chairs: Drs. Ruth Ross and Allyn Howlett Itai Bab, Joseph Tam, Orr Ofek, Catherine Ledent, Ester Fride, Yankel Gabet, Ralph INVOLVEMENT OF CB1 SIGNALLING 9.00 Müller, Andreas Zimmer, Ken Mackie, IN BONE REMODELLING 5 Raphael Mechoulam and Esther Shohami Sharon Anavi-Goffer, Daniel Fleischer, Dow P.
    [Show full text]
  • JPET #158162 1 Blockade of 2-AG Hydrolysis by Selective
    JPET Fast Forward. Published on August 7, 2009 as DOI:10.1124/jpet.109.158162 JPET #158162 Blockade of 2-AG hydrolysis by selective monoacylglycerol lipase inhibitor JZL184 enhances retrograde endocannabinoid signaling Bin Pan, Wei Wang, Jonathan Z Long, Dalong Sun, Cecilia J Hillard, Benjamin F Cravatt and Qing-song Liu Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA (B.P., W.W., D.S., C.J.H., Q.S.L.); The Skaggs Institute for Chemical Biology, Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA (J.Z.L., B.F.C.) 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. JPET #158162 Running title: MAGL inhibitor JZL184 potentiates DSE/DSI Corresponding author: Qing-song Liu, Ph.D., Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA Phone: (414) 456-8877; Fax: (414) 456-6545; E-mail: [email protected] Number of pages: 25; Number of figure: 5; Number of references: 40. Word Count: Abstract = 208; Introduction = 562; Discussion = 1139 Non-standard Abbreviations: 2-AG, 2-arachidonoylglycerol; ACSF, artificial cerebrospinal Fluid; AEA, N- arachidonoylethanolamine; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; COX-2, cyclooxygenase-2; DAG, diacylglycerol; D-AP-5, D-2-amino-5-phosphonovaleric acid; DSE, depolarization-induced suppression of excitation; DSI, depolarization-induced suppression of inhibition; eCB, endocannabinoid; EPSCs, excitatory postsynaptic currents; FAAH, fatty acid amide hydrolase; IPSCs, inhibitory postsynaptic currents; MAFP, methyl arachidonyl fluorophosphonate; MAGL, monoacylglycerol lipase.
    [Show full text]
  • Design, Synthesis and Biological Evaluation of Heterocyclic Derivatives As Potential MAGL Inhibitors
    UNIVERSITÀ DEGLI STUDI DI PISA Facoltà di Farmacia Corso di Laurea Specialistica in Chimica e Tecnologia Farmaceutiche Tesi di Laurea: Design, synthesis and biological evaluation of heterocyclic derivatives as potential MAGL inhibitors. Relatori: Candidato: Prof.ssa Clementina Manera Gianfilippo Martello Dott.ssa Francesca Castelli ANNO ACCADEMICO 2010/2011 Design, synthesis and biological evaluation of heterocyclic derivatives as potential MAGL inhibitors. Gianfilippo Martello A mio cugino Fabio e alla mia famiglia… Pagina 2 di 72 Design, synthesis and biological evaluation of heterocyclic derivatives as potential MAGL inhibitors. Gianfilippo Martello Sommario 1. Introduction .................................................................................................................................. 5 1.1 Description ............................................................................................................................ 5 1.2 Taxonomy .............................................................................................................................. 6 1.3 Endocannabinoid system (ECS) ............................................................................................. 7 1.4 MAGL ..................................................................................................................................... 9 1.4.1 Structure and most important residues ........................................................................ 9 1.4.2 Binding of the natural substrate .................................................................................
    [Show full text]
  • WO 2014/057067 Al 17 April 2014 (17.04.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/057067 Al 17 April 2014 (17.04.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/127 (2006.01) A61K 31/35 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/20 (2006.01) A61K 47/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/232 (2006.01) A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/EP20 13/07 1223 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 10 October 2013 (10.10.201 3) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12188038.9 10 October 2012 (10. 10.2012) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: MAX-PLANCK-GESELLSCHAFT ZUR UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, FORDERUNG DER WISSENSCHAFTEN E.V.
    [Show full text]
  • Endothelium-Dependent Metabolism by Endocannabinoid Hydrolases and Cyclooxygenases Limits Vasorelaxation to Anandamide and 2-Arachidonoylglycerol
    British Journal of Pharmacology (2007) 150, 641–651 & 2007 Nature Publishing Group All rights reserved 0007–1188/07 $30.00 www.brjpharmacol.org RESEARCH PAPER Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol W-SV Ho and MD Randall School of Biomedical Sciences, University of Nottingham Medical School, Queen’s Medical Centre, Nottingham, UK Background and purpose: The endocannabinoids, N-arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG) are rapidly degraded by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). Whilst these lipid mediators are known to modulate vascular tone, the extent to which they are inactivated via local metabolism in the vasculature remains unclear. Experimental approach: In rat isolated small mesenteric arteries, the regulatory role of FAAH, MGL and cyclooxygenase (COX) in relaxant responses to anandamide and 2-AG was evaluated by using inhibitors of these enzymes. Relaxations to non- hydrolysable analogues of endocannabinoids and arachidonic acid were also examined. Key results: Relaxation to anandamide but not 2-AG was potentiated by the selective FAAH inhibitor, URB597 (1 mM). In contrast, MAFP (10 mM; an inhibitor of FAAH and MGL) enhanced responses to both anandamide and 2-AG. Inhibition of COX-1 by indomethacin (10 mM) potentiated relaxations to 2-AG, whereas inhibition of COX-2 by nimesulide (10 mM) potentiated anandamide-induced relaxation. With the exception of MAFP, effects of FAAH and COX inhibitors were dependent on the endothelium. Relaxation to methanandamide and noladin ether, the non-hydrolysable analogues of anandamide and 2-AG respectively, were insensitive to the enzyme inhibitors.
    [Show full text]
  • Monoacylglycerol Lipase Inhibition by Organophosphorus Compounds Leads to Elevation of Brain 2-Arachidonoylglycerol and the Associated Hypomotility in Mice
    Toxicology and Applied Pharmacology 211 (2006) 78–83 www.elsevier.com/locate/ytaap Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice Gary B. Quistad, Rebecka Klintenberg, Pierluigi Caboni, Shannon N. Liang, John E. Casida ⁎ Environmental Chemistry and Toxicology Laboratory, Department of Environmental Science, Policy and Management, University of California, 115 Wellman Hall, Berkeley, CA 94720-3112, USA Received 27 September 2005; revised 24 October 2005; accepted 24 October 2005 Available online 28 November 2005 Abstract Three components of the cannabinoid system are sensitive to selected organophosphorus (OP) compounds: monoacylglycerol (MAG) lipase that hydrolyzes the major endogenous agonist 2-arachidonoylglycerol (2-AG); fatty acid amide hydrolase (FAAH) that cleaves the agonist anandamide present in smaller amounts; the CB1 receptor itself. This investigation considers which component of the cannabinoid system is the most likely contributor to OP-induced hypomotility in mice. Structure–activity studies by our laboratory and others rule against major involvement of a direct toxicant–CB1 receptor interaction for selected OPs. Attention was therefore focused on the OP sensitivities of MAG lipase and FAAH, assaying 19 structurally diverse OP chemicals (pesticides, their metabolites and designer compounds) for in vitro inhibition of both enzymes. Remarkably high potency and low selectivity is observed with three O-alkyl (C1,C2,C3) alkylphosphonofluoridates (C8,C12) (IC50 0.60–3.0 nM), five S-alkyl (C5,C7, C9) and alkyl (C10,C12) benzodioxaphosphorin oxides (IC50 0.15–5.7 nM) and one OP insecticide metabolite (chlorpyrifos oxon, IC50 34–40 nM). In ip-treated mice, the OPs at 1–30 mg/kg more potently inhibit brain FAAH than MAG lipase, but FAAH inhibition is not correlated with hypomotility.
    [Show full text]
  • Synthetic Drugs [I.E
    Synthetic Drug Trafficking & Abuse Trends July 13 -14, 2013 Pharmacy Diversion Awareness Conference (PDAC) Portland, OR. Alan G. Santos, Associate Deputy Assistant Administrator, Operations Division, Office of Diversion Control, U.S. Drug Enforcement Administration Outline • Synthetic Cannabinoids • Synthetic Cathinones • Other Synthetic Compounds • Scope of the Problem • Control Efforts: Federal, State, & International U.S. Drug Enforcement Administration / Operations Division / Office of Diversion Control Designer Drugs: A Tough Problem Targeting emerging psychoactive designer synthetic drugs [i.e. synthetic cannabinoids (the synthetic marijuana compounds), synthetic cathinones (the synthetic stimulants), and other emerging synthetic compounds] is a priority for DEA. But it’s a tough public health & safety challenge! U.S. Drug Enforcement Administration / Operations Division / Office of Diversion Control UNODC: NPS are substances of abuse that are not under international control (but constitute a significant public health threat) U.S. Drug Enforcement Administration / Operations Division / Office of Diversion Control Designer Drugs These drugs are perceived as being ‘legal’ alternatives to marijuana, cocaine, methamphetamine, and MDMA. U.S. Drug Enforcement Administration / Operations Division / Office of Diversion Control Proliferation of Designer Drugs • Increasingly popular among recreational drug users • Internet sales • Head shops/Smoke shops • Promoted by discussion boards – self studies Armed with medical research and fueled by Chinese factories And YouTube, a band of outlaws has Created a dangerous multibillion-dollar industry 9/5/2013 6 Designer Drugs: Where did they come from ? A highly regarded Medicinal Chemist Dr. F. Ivy Carroll and colleagues stated in a recent publication: Throughout the drug discovery process, pharmaceutical companies, academic institutions, research institutions, and other organizations publish their studies in scientific journals, books, and patents.
    [Show full text]